Short interest for Natural Health Trends gives investors a sense of the degree to which investors are betting on the decline of Natural Health Trends's stock. Short interest data is updated every two weeks.

Natural Health Trends Stock (NASDAQ:NHTC), Short Interest Report

Natural Health Trends

Natural Health Trends Corp is an international direct-selling and e-commerce company. It offers a line of products such as Wellness, Herbal, Beauty, Lifestyle, and Home. Wellness products include targeted nutrition for joint health, antioxidant support, digestive health, heart health, and vision health. Herbal products include anti-aging and hydrating cleansers, creams, lotions, serums, and toners. Lifestyle products improve the overall quality of life and to support active, physical and healthy lifestyles. Home products are designed to create a clean and natural living environment for the home. It generates a majority of its revenue from Hong Kong and rest from China, Taiwan, Japan, United States and other regions.

News

Penny Stocks

Short Ideas

Pre-Market Outlook

Markets

Trading Ideas

NHTC

As of Jan. 30, 2024, three stocks in the consumer staples sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions.

Top 3 Defensive Stocks That Could Sink Your Portfolio In Q1

COKE

NOMD

As of Jan. 17, 2024, three stocks in the consumer staples sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions.

Top 3 Defensive Stocks That May Fall Off A Cliff This Quarter

Small Cap

Intraday Update

Movers

AMAM

AMCX

APGN

APLT

ARQQ

AXLA

AXTI

BOXD

CGNX

CISO

CPOP

CYAD

CYTH

DKNG

DZSI

EBET

HUBS

IBIO

INZY

ISEE

KNSL

LANV

LUNR

MRNA

NOGN

RMAX

SBET

SPRC

STEM

STSA

TFFP

UEIC

VGAS

VNRX

Gainers


	Ibio Inc (NYSE: IBIO) shares rose 97% to $1.4787 after the company announced MUC16 as its latest immune-oncology target program.


Why Universal Electronics Shares Are Trading Lower By 30%? Here Are Other Stocks Moving In Friday&#39;s Mid-Day Session

Natural Health Trends Corp. - Commn Stock

Natural Health Trends Corp

The largest U.S. drugstore chain, CVS Health (CVS), will release its fourth-quarter results on February 7. The company is expected to report year-over-year growth in revenue and earnings. With the expected rise in medical costs during the fourth quarter, should investors consider buying the stock now? Read on to learn my view… CVS Health Corporation (<a href="https://stocknews.com/stock/CVS/">CVS</a>) is scheduled to report its fourth-quarter and full-year results on February 7. Wall Street expects the healthcare major's revenue and EPS to increase year-over-year. In this piece, I have discussed why it could be wise to wait for a better entry point in the stock despite the expected rise in revenue and earnings.
For the fourth quarter, CVS' EPS is expected to increase 0.1% year-over-year to $1.99. Similarly, its revenue for the same quarter is expected to increase 7.9% year-over-year to $90.46 billion. The company has a solid earnings history, having beaten the consensus estimate in each of the trailing four quarters.
After reporting its third quarter results, CVS Health President and CEO Karen S. Lynch said, "Despite a challenging business environment, we continue adapting to the changing needs of our consumers by connecting our care delivery capabilities in communities across the country, broadening access to care and lowering costs."
The company said that its fourth-quarter medical costs would be <a href="https://www.bloomberg.com/news/articles/2024-01-08/health-insurers-drop-after-cvs-warns-of-higher-medical-costs">higher than previously expected</a>. Also, it forecasted that its medical-loss ratio or medical-benefit ratio would be 87.2% this year.
CVS revised its full-year 2023 GAAP EPS guidance range to between $6.37 and $6.61 from between $6.53 and $6.75. It reaffirmed its fiscal 2023 adjusted EPS guidance range of between $8.50 and $8.70. The company also confirmed its cash flow from operations guidance for fiscal 2023 of $12.50 billion and $13.50 billion.
It expects its total company revenue for the full-year 2023 to come between $351.50 billion and $357.30 billion. Also, its adjusted operating income is likely to come between $17.20 billion and $17.60 billion.
In August, the company launched Cordavis, a wholly-owned subsidiary that will work with pharmaceutical manufacturers to commercialize and/or co-produce biosimilar products for the U.S. market.
At its 2023 Investor Day, CVS introduced CostVantage and CVS Caremark TrueCost to drive aligned incentives and deliver a more transparent and sustainable reimbursement model. It also launched the CVS Healthspire brand for the Health Services segment that simplifies access to multi-payor capabilities, better aligns client service, and helps drive better outcomes and greater lifetime value.
CVS Health President and CEO Karen S. Lynch said, "We are successfully executing on our strategy to advance the future of health care while unlocking new value for consumers. The combination of our businesses and the key growth areas we have invested in drive our ability to lower the total cost of care, improve health outcomes, and deliver on our commitments to our customers, consumers, and shareholders."
For fiscal 2024, the company expects total revenues of approximately $366 billion. Its adjusted operating income is likely to be at least $17.20 billion. Also, its adjusted EPS is expected to be at least $7.26. In addition, its cash flow from operations is expected to be approximately $12.50 billion.
CVS' stock has gained 4% over the past three months and declined 15.9% over the past year to close the last trading session at $72.44.
Here's what you might want to consider ahead of its upcoming earnings release:
Mixed Financials
CVS' total revenues for the fiscal third quarter ended September 30, 2023, rising 10.6% year-over-year to $89.64 billion. Its adjusted operating income increased 2.5% over the prior-year quarter to $4.46 billion. Also, its adjusted EPS came in at $2.21, representing an increase of 1.8% year-over-year.
On the other hand, the company's adjusted net income decreased 0.7% year-over-year to $2.85 billion. In addition, its Health Care Benefits segment's adjusted operating income declined 6.4% year-over-year to $1.54 billion.
Mixed Analyst Estimates
Analysts expect CVS' EPS for fiscal 2023 and 2024 to decline 1% and 1.3% year-over-year to $8.60 and $8.50, respectively. Its fiscal 2023 and 2024 revenue is expected to increase 9.9% and 2.3% year-over-year to $354.42 billion and $362.59 billion, respectively.
Discounted Valuation
In terms of forward non-GAAP P/E, CVS' 8.50x is 54.7% lower than the 18.74x industry average. Its 7.92x forward EV/EBITDA is 40.5% lower than the 13.31x industry average. Likewise, its 9.09x forward EV/EBIT is 45.6% lower than the 16.72x industry average.
Mixed Profitability
In terms of the trailing-12-month <a href="https://www.investopedia.com/terms/e/ebitda.asp">EBITDA</a> margin, CVS' 5.29% is 3.2% higher than the 5.13% industry average. Likewise, its 1.44x trailing-12-month asset turnover ratio is 268.3% higher than the industry average of 0.39x.
CVS' 0.81% trailing-12-month Capex/Sales is 80.6% lower than the 4.18% industry average. Likewise, its 15.29% trailing-12-month gross profit margin is 73.3% lower than the 57.28% industry average. Furthermore, the stock's 2.44% trailing-12-month net income margin compares to the negative industry average of 5.56%.
POWR Ratings Reflect Uncertainty
CVS has an overall rating of C, equating to a Neutral in our <a href="https://stocknews.com/powr-ratings/">POWR Ratings</a> system. The POWR Ratings are calculated by considering 118 different factors, each weighted to an optimal degree.
Our proprietary rating system also evaluates each stock based on eight distinct categories. CVS has a C grade for Quality, consistent with its mixed profitability.
It has a C grade for Sentiment, in sync with its mixed analyst estimates.
CVS is ranked first out of 3 stocks in the <a href="https://stocknews.com/category/drug-stores/">Medical – Drug Stores</a> industry. <a href="https://stocknews.com/stock/CVS/">Click here</a> to access CVS' Growth, Value, Momentum, and Stability ratings.
Bottom Line
CVS expects its growth to be driven by Cordavis, which offers affordable biosimilars. However, its Pharmacy and Consumer Wellness segment continues to face margin pressure due to factors like continued pharmacy reimbursement pressure, the impact of recent generic introductions, a decrease in store counts, etc. Moreover, the company is expected to keep facing headwinds in the healthcare benefits business.
Although CVS currently trades at a discounted valuation, it could be wise to wait for a better entry point in the stock, given its mixed financials, analyst estimates, and profitability.
How Does CVS Health Corporation (CVS) Stack Up Against Its Peers?
CVS has an overall POWR Rating of C, equating to a Neutral rating. You may check out these A and B-rated stocks within the <a href="https://stocknews.com/category/medical-consumer-goods/">Medical – Consumer Goods</a> industry: Nature's Sunshine Products, Inc. (<a href="https://stocknews.com/stock/NATR/">NATR</a>), LifeVantage Corporation (<a href="https://stocknews.com/stock/LFVN/">LFVN</a>), and Natural Health Trends Corp. (<a href="https://stocknews.com/stock/NHTC/">NHTC</a>). For exploring more Buy-rated Medical – Consumer Goods stocks, <a href="https://stocknews.com/category/medical-consumer-goods/">click here</a>.
What To Do Next?
43 year investment veteran, Steve Reitmeister, has just released his 2024 market outlook along with trading plan and top 11 picks for the year ahead.
<a href="https://report.stocknews.com/sign-up/stock-market-outlook-2024/?formplacement=artbotad_smo24_rep%22">2024 Stock Market Outlook &gt;</a>

<hr />
CVS shares were trading at $73.44 per share on Tuesday morning, up $1.00 (+1.38%). Year-to-date, CVS has declined -6.15%, versus a 3.65% rise in the benchmark S&amp;P 500 index during the same period.
<hr><div style="clear:both;"></div> <h2>About the Author: Dipanjan Banchur</h2> <img src='https:/wp-content/uploads/2021/11/Dipanjan-Banchur_headshots_3.jpg' style="float:left; padding:5px;width:125px;">Since he was in grade school, Dipanjan was interested in the stock market. This led to him obtaining a master's degree in Finance and Accounting. Currently, as an investment analyst and financial journalist, Dipanjan has a strong interest in reading and analyzing emerging trends in financial markets.<a href="https://stocknews.com/authors/?author=dipanjan-banchur">More...</a>The post <a href=https://stocknews.com/news/cvs-natr-lfvn-nhtc-cvs-health-cvs-pre-earnings-analysis-buy-or-hold/>CVS Health (CVS) Pre-Earnings Analysis: Buy or Hold?</a> appeared first on <a href=https://stocknews.com/>StockNews.com</a>

CVS Health (CVS) Pre-Earnings Analysis: Buy or Hold?

Natural Health Trends GAAP EPS of $0.03, revenue of $10.9M

Natural Health Trends Corp. (NHTC) Q4 2023 Earnings Call Transcript

Natural Health Trends goes ex dividend tomorrow

Natural Health Trends (NHTC) just unveiled an announcement. The Compensation Committee of Natural Health Trends Corp. has approved a special waiver...

Natural Health Trends Grants Stock Transfer Waiver for President

Notable earnings before Wednesday's open

Natural Health Trends GAAP EPS of $0.02, revenue of $11M

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Natural Health Trends (NASDAQ:<a href="https://investorplace.com/stock-quotes/nhtc-stock-quote/">NHTC</a>) just reported results for the first quarter of 2024.<ul><li>Natural Health Trends reported earnings per share of 2 cents.</li><li>The company reported revenue of $10.95 million.</li></ul><div>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT771245">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT771236">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2021/01/one-percenter-issues-urgent-warning/?cid=MKT499868&amp;eid=MKT793997">It doesn&rsquo;t matter if you have $500 or $5 million. Do this now.</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	The post <a href="https://investorplace.com/earning-results/2024/05/nhtc-stock-earnings-natural-health-trends-for-q1-of-2024/">NHTC Stock Earnings: Natural Health Trends Reported Results for Q1 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

NHTC Stock Earnings: Natural Health Trends Reported Results for Q1 2024

Natural Health Trends Corp. (NHTC) Q1 2024 Earnings Call Transcript

Natural Health Trends declares $0.20 dividend

ALKS

AMRN

AXTA

BIPC

BLCO

BRSP

CENX

CHEF

CMRX

CNDT

COCO

DFIN

EEFT

ENTG

EXTR

FLEX

GNRC

GRMN

GTHX

IDXX

LFVN

LIVN

MTRN

NATR

NBIX

NCLH

PUMP

RGEN

ROCK

SHOO

SITE

SLGN

SMMT

STGW

TCPC

TECH

TRIN

TTMI

USAP

UTHR

Press Releases

Natural Health Trends to Report Second Quarter 2023 Financial Results on August 2nd

Earnings

Natural Health Trends Reports Second Quarter 2023 Financial Results

Opinion

Thinking about buying stock in Profire Energy, Natural Health Trends, Genius Group, Upstart Holdings, or Wework?

Natural Health Trends to Report Third Quarter 2023 Financial Results on November 1st

Natural Health Trends Reports Third Quarter 2023 Financial Results

Natural Health Trends to Report Fourth Quarter 2023 Financial Results on February 7th

Natural Health Trends Reports Fourth Quarter and Full Year 2023 Financial Results

Natural Health Trends to Report First Quarter 2024 Financial Results on May 1st

Natural Health Trends Reports First Quarter 2024 Financial Results

GENSY

PFIE

UPST

AXIL Brands

BellRing Brands

Coty

Estee Lauder Companies, Inc. (The) Common Stock

Estee Lauder Cos

e.l.f. Beauty

Edgewell Personal Care Company Common Stock

Edgewell Personal Care

FitLife Brands

Herbalife

Haleon plc American Depositary Shares (Each representing two Ordinary Shares)

Haleon

Honest Co

Inter Parfums

Kenvue

Lifevantage

Medifast

Natural Alternatives International, Inc. - Common Stock

Natural Alternatives Intl

Nature's Sunshine Products, Inc. - Common Stock

Natures Sunshine Products

Nu Skin Enterprises

Olaplex Hldgs

Safety Shot

The Beauty Health Company - Class A Common Stock

Beauty Health

Unilever

Usana Health Sciences

Veru

Waldencast

Yatsen Holding Limited American Depositary Shares, each representing twenty (20) Class A Ordinary Shares

Yatsen Holding

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Natural Health Trends Stock (NASDAQ:NHTC), Short Interest Report

People Also Watch